WASHINGTON (AP) - The Food and Drug Administration on Monday expanded approval of a Bayer cancer pill to treat tumors of the intestinal tract that don't respond to other treatments.
The drug is called Stivarga and regulators approved it to treat gastrointestinal stromal tumors that cannot be surgically removed and no longer respond to other FDA-approved drugs.
The FDA previously approved Stivarga to treat colorectal cancer. It works by blocking several enzymes that promote cancer growth.
The FDA approved the drug for the new use based on a study of nearly 200 patients who were randomly assigned to take Stivarga or a placebo pill.
Patients taking the drug experienced a nearly four month delay in the growth of their tumors compared to taking placebo.
The most common side effects of Stivarga in clinical trials included liver damage, severe bleeding, blistering and peeling of skin, high blood pressure, heart attacks and perforations.
Other drugs approved to treat intestinal tumors include Gleevec and Sutent, both made by Pfizer Inc.
Bayer HealthCare is a subsidiary of Germany's Bayer AG
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
An airman from Niagara Falls was away training for the Air Force for months. After being apart from his family, he decided to surprise them at Kelly’s Country Store in Grand Island.
A Buffalo city jail cell block attendant was arrested early Saturday morning on multiple animal cruelty charges.
Family and friends created a memorial for James complete with notes and candles.
Detectives say Brandon Cahee, 28, was found in an upper apartment of a home on Ericson Avenue, and he had been shot.
It's been one month since Typhoon Haiyan barreled through the Philippines, leveling towns and killing nearly 6,000 people.
Rookie Mike Glennon rebounded from one of his worst performances of the season to throw two touchdown passes and lead the Tampa Bay Buccaneers a 27-6 victory over the struggling Buffalo Bills on Sunday.